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O r i g i n a l  r e p O r t
Automation in the transfusion 
service
S.H. ButcH
Several instruments are now available for full automation of 
serologic testing in the transfusion service.  Selection of an 
instrument is based on the facility’s needs for testing and its 
resources.  Installation, validation, interfacing, and operations 
require new skill sets for most transfusion service person-
nel.  The newer instruments are suitable for use in smaller 
transfusion services, where procedures may not have changed 
recently and installing new equipment is a rarity.  It is difficult 
to compare turnaround times and the cost of operating the 
instrument because the number of specimens and specific tests 
per run and test optimization features of the instrument’s soft-
ware all can vary.  Automated instruments have proved to be 
suitable for testing most, but not all, specimens submitted for 
testing.  While automation reduces overall turnaround time, the 
quickest way to determine a patient’s blood type remains the 
manual tube test.  Autoverification of results and placing these 
instruments in an automation line in a core laboratory may lie 
in the future.  Immunohematology 2008;24:86–92.
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Automation of serologic testing has many ad-
vantages, including improved quality management. 
With fewer manual steps, standardization of testing, 
and the ability to review saved images of test results, 
errors are reduced and problems are more easily 
traced.  While a few automated and semiautomated 
instruments have been available for more than 10 
years, instruments that perform a full range of test-
ing and are suitable for use in the transfusion service 
have been available in the United States only in the 
last 5 years.  There now are available a number of 
systems to perform automated serologic testing in 
the transfusion service.  Purchasing, installing, vali-
dating, and using automation present challenges to 
transfusion service personnel more familiar with 
manual testing.
Transfusion Service Instrumentation
Three manufacturers currently make available 
four instruments for use in a transfusion service in 
the United States.  Table 1 lists the instruments and 
various attributes.  The information in this table was 
obtained from a variety of sources and is believed 
to be current at the time of this writing.  However, 
new capabilities may have been introduced and ad-
ditional testing and features may now be available. 
Not included in this list are semiautomated instru-
ments, those that perform ABO and D typing only or 
antibody screening only, and instruments that are no 
longer marketed and supported by their vendors.
The currently available instruments perform 
ABO and D typing, antibody screening, antibody 
identification, antigen typing, donor ABO/D recon-
firmation, and direct antiglobulin testing (DAT). 
Some instruments perform IgG crossmatching.  Each 
instrument is unique and their platforms (solid 
phase, gel column, and microtiter plates) differ.  The 
Galileo (Immucor, Norcross, GA) appears to be an 
instrument suited to a blood bank that both collects 
donor units and performs pretransfusion testing.  The 
Echo (Immucor), ProVue (Ortho-Clinical Diagnostics, 
Raritan, NJ), and Tango Optimo (Biotest Diagnostics, 
Rockaway, NJ) are intended primarily to be used in a 
transfusion service, but they could be used in facili-
ties that collect a smaller number of donor units.
Selection
The transfusion service now joins the other 
sections of the clinical laboratory vying for large 
capital equipment funding.  However, our colleagues 
in the other laboratory sections can provide useful 
information about the process of selecting, financing, 
installing, validating, and operating instrumentation. 
Table 2 lists a number of issues to be considered in 
the selection process.
Instrument selection is based on the individual in-
stitution’s needs and available resources.  Developing 
a list of operating needs, such as turnaround time, 
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Table 1. Instrument features
 Galileo ECHO ProVue Tango
Test menu
ABO Yes Yes Yes Yes
D Yes Yes Yes Yes
Antibody screen Pooled, 2-cell, 3-cell, 4-cell 3-cell plus control Pooled, 2-cell or 3-cell Pooled, 2-cell or 3-cell
Antigen typing Rh phenotype test of  Rh/Kell phenotype Yes Yes 
 record/antigen screening
Panels Yes, 3 precoated panels Yes, precoated panels Yes Yes 
 available available
Other testing Weak D, DAT, CMV, syphilis Weak D, DAT Weak D, DAT Weak D, DAT
Crossmatch IgG IgG IgG IgG
Unit ABO/D Yes Yes Yes Yes 
confirmation
Platform
 Floor model Benchtop Benchtop Benchtop
  Hemagglutination for  Hemagglutination for  Gel Dried antisera in wells for 
antigens and solid phase  antigens and solid phase   antigens, Solid screen II 
for antiglobulin phase  for antiglobulin phase   for antiglobulin phase
 Fully automated  Fully automated  Fully automated  Fully automated
 Continuous access via  Continuous access via  Batch or single specimen  Single specimen stat 
 linear sample and reagent linear sample and reagent  capability 
 racks  racks
 Dynamic scheduler  STAT priority  Stat interrupt capability  3-color CCD camera
 Image analysis reader  Image analysis reader  Black-and-white images
System liquid
 PBS  PBS  Gel card diluent
 Can be filled while  Can be filled while 
 instrument is processing  instrument is processing
 Can accommodate a 20L 
 saline cube
Specimen
Specimen type  EDTA  EDTA  EDTA, citrate, and serum  EDTA, citrate, and serum
Specimen size  12–17 mm diameter,  12–16 mm diameter,  12–16 mm diameter,  10–16 mm diameter, 
 75–100 mm length,  75–100 mm length,  75–100 mm max  105 mm high, 
 pediatric microtainers  pediatric microtainers   pediatric containers
Sample capacity  224, continuous feed  20, continuous feed  12 per run; 48 per carousel  144 samples in 12 racks
Sample barcodes  Codabar, Code 128,   Codabar, Code 128,  Codabar, ISBT 128,  Eurocode 128, 128 C, 
 Code 39, Interleaved 2 of 5,  Code 39, Interleaved 2 of 5,  Code 39, plus others Codabar, Code 39,  
 ISBT 128  ISBT 128    Interleaved 2 of 5
Turnaround time
Time for first ABO/D  22 minutes  11 minutes  35–40 minutes  17 minutes
Time for antibody screen  40 minutes  20 minutes  35–40 minutes  31 minutes
Specimens/hour  Variable, dependent on  Variable, dependent on  Variable, dependent on  12 type and screens/ 
 number of samples and  number of samples and  number of samples and  64 minutes 
 test mix; average of 60 type  test mix; average of 16 type  test mix 
 and screens/hour  and screens/hour
STAT time  Variable  Variable, typically less  Variable  Has two stat functions 
  than 45 minutes
Interface
   ASTM  ASTM
Unidirectional  Yes  Yes  Yes  Yes 
interfaces to LIS
Bidirectional  Yes  Yes  Yes  Yes 
interfaces to LIS
    Host query
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Table 2. Considerations in instrument selection
Platform and test methods
Physical space and electrical requirements
Tests to be automated
Stat processing capability





LIS* interface capability and cost
Training requirements and costs
Vendor assistance in validation and training
Maintenance and service agreements
Mean time between failures (if current operational data are available)
*Laboratory information system
stat capability, cost, specificity, and sensitivity, is 
essential to selecting the correct instrument and 
measuring the effectiveness of the process after 
implementation.
Quality assessment tools and Lean concepts,1 
if applied from the early planning stages through 
postimplementation assessment, assist in redefining 
processes, selecting performance measures, and 
evaluating goals.2,3  Defining the current process 
as well as the proposed new process is a necessary 
planning step.  Before-and-after layouts of the flow 
of specimens and information help identify needs 
for space reconfiguration, computers, new furniture, 
and the location of reagent storage.  For budgeting 
purposes, these expenses may be combined into the 
instrument acquisition cost or funded separately, de-
pending on the budgeting process the facility uses.
Conducting site visits to and telephone interviews 
of current users are helpful in identifying valu-
able features and actual user experience in routine 
operation of the instrument.  Providing the facility 
being queried with a list of questions based on the 
anticipated use of the instrument allows this facility 
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Table 1 continued.     Instrument features
 Galileo ECHO ProVue Tango
Quality controls 
available
 Yes, premanufactured  Yes, premanufactured  Yes
  Whole blood daily run  Once daily  Once daily 
  controls can be processed 
  with samples
Special features
 Touchscreen user interface  Touchscreen user interface  Mouse and keyboard  Touch screen user interface 
   interface
 2 pipetting arms  Real-time barcode read  Probe impact sensor under  Reagents on board for 7 days 
   development  (except bromelin)
 Real-time barcode read  Instant access: samples,  Reverification of reagents  System monitors onboard 
  reagents, and supplies can  and specimens when the  storage 
  be loaded at any time;  door is opened 
  samples can be removed as  
  soon as pipetting is complete
 Instant access: samples,  Real-time test results  Stat goes to the top of the  Two probes, two pipetting 
 reagents, and supplies can   pending pipetting list  arms 
 be loaded at any time; 
 samples can be removed as 
 soon as pipetting is complete
 Real-time test results  Reflex testing
 Reflex testing  Pediatric sample racks
 Pediatric sample racks  Blud_Direct Remote 
  Diagnostics
 Blud_Direct Remote  Customer changeable parts 
 Diagnostics
 Probe can be changed by 
 customer
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to gather data and provide a more accurate response. 
Another resource is a Web search for current pub-
lished abstracts and papers, using PubMed.  And the 
Web site http://www.accessdata.fda.gov/scripts/cdrh/
cfdocs/cfMAUDE/search.CFM can be used to investi-
gate problems with various instruments reported in 
the MedWatch program.  The listings can provide 
insights into user problems, installation issues, and 
repair problems.  Note that there is a correlation 
between the number of instruments in the field and 
the number of reports.
Choosing the platform, microtiter plate or gel 
column, is a major decision.  While gel seems to be 
more sensitive to Rh and warm autoantibodies, solid 
phase and microtiter seem to be more sensitive to 
cold-reactive antibodies.4,5  Both microtiter plate and 
gel column platforms have been reported to miss a 
clinically significant antibody, supporting the long-
held belief that no one technique will identify all 
antibodies.6–8
Interfacing
All of the instruments are capable of being inter-
faced with one or more laboratory information sys-
tems (LIS).  There are additional costs for interfacing 
instruments with a LIS.  Each interface is considered 
unique and LIS vendors usually charge per instru-
ment interfaced.  The learning curve has been very 
steep for the first facilities attempting to interface 
instruments.  None of the interfaces are easy and 
“plug and play” does not exist.  As more instruments 
are interfaced, interfacing should become easier. 
Current users of the same instruments and same spe-
cific versions of LIS software are the best resource 
for learning about issues in interfacing that software- 
instrument pair.  However, even when using the same 
equipment vendor and transfusion service software, 
setting up each interface can present new challenges 
because facilities operate differently.  Options within 
the transfusion service software such as decision 
tables and other features (i.e., whether the ABO/D in-
terpretation, the individual detail results, or both are 
sent) may be set differently for different facilities.
Turnaround Times
It is difficult to compare turnaround time between 
instruments as it depends on the number of speci-
mens being processed and the tests being performed. 
Instruments differ in the number of specimens with 
different testing requirements that can be run at the 
same time.  Some instruments allow specimens to be 
run as a priority, or stat.  The instrument software 
then optimizes the output of results for this specimen. 
This may or may not result in a significant reduction 
in processing time.  Manual tube testing still provides 
the fastest method of obtaining a type and screen. 
However, the average turnaround time for a test will 
decrease and it is likely that most specimens can be 
run on the automated instruments, even if they are 
marked stat.9,10
Estimating Costs
Probably the most difficult aspect of the investi-
gation process is estimating the cost of operating the 
instrument.  Expenses vary widely and depend on 
the number of tests in the average run; the number 
of wasted wells in microtiter plates; the frequency 
and number of controls that must be run; the cost 
of reagents and diluents, which vary with contract 
tiers; and the number of repeat tests performed. 
Additional costs are associated with remodeling the 
workplace and service contracts.  While automation 
has been marketed as a way of reducing total costs by 
reducing the number of staff members in a transfu-
sion service, it is unlikely that staff members will be 
eliminated.  Automation will improve process control 
and quality management, reduce stress, provide the 
ability to absorb additional testing, and allow re- 
allocation of staff to other projects such as increased 
quality monitoring.
Critical to the selection process is the backup 
testing process used when instrumentation is not 
operational.  Even if there is no downtime for instru-
ment malfunction, there is periodic maintenance and 
there may be a need to test specimens that some 
instruments cannot process due to specimen quantity 
or quality (severe lipemia, hemolysis).  If the manual 
tube method using a 5% RBC suspension is used to 
back up an automated system using 0.8% RBCs in a 
gel system, two sets of RBCs must be stocked.  Larger 
institutions may consider purchasing two instru-
ments, as this is the ideal backup system.  But even 
then, a manual backup system should be in place.
Computer and Interface Issues
It may be necessary to make changes in the 
computer system to accommodate automated testing. 
If multiple instruments are used to perform test-
ing, the instrument used for a specific test must be 
traceable.  While a footnote on an order or test result 
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could work, it is probably best to build the tests in 
the LIS so that the result can be identified as coming 
from a specific instrument, as is done in the general 
laboratory.
Of critical importance is determining whether 
the automated instrument or the LIS interprets the 
testing results.  For the LIS to interpret results, the 
individual test results (4+, 0, hemolysis, etc.) must 
be sent to the LIS.  The value of using the LIS to in-
terpret results is that the interpretation is controlled 
by the laboratory, not the instrument vendor.  For 
example, it may be the policy of a hospital to inter-
pret a weak D reaction as D– where the instrument 
might interpret it as D+.  If the instrument sent only 
the interpretation, the algorithms set up in the LIS 
to meet the institutional policies would not operate. 
The validation strategy is influenced by which device 
interprets the results.
As our colleagues in donor centers have long ap-
preciated, interfacing instruments to an information 
system can be frustrating, taking a year or more.2 
This is especially true if the interface between that 
LIS version and the specific instrument has not been 
done previously.
Unidirectional and bidirectional interfaces may 
be used.  In the unidirectional interface, test results 
are uploaded after being completed.  The bidirec-
tional interface downloads data on ordered tests and 
uploads the results.  Middleware may be needed in 
some cases to translate the information sent by the 
instrument to a format understandable to the LIS. 
The process flow changes depending on whether 
the instrument is interfaced as well as on the type 
of interface.  Whenever data are entered manually, 
there should be an ongoing process to ensure that 
they are entered correctly.
The Test Specimen
If the institution is still using a clotted specimen 
for testing blood bank specimens, a significant hurdle 
may be changing to an EDTA tube.  Pink-stoppered 
EDTA tubes are available.  They assist in separating 
tubes intended for hematology from those intended 
for the transfusion service. In addition, pink-top 
tubes have a larger specimen volume than the laven-
der tubes.  Test requisitions, computerized test order 
sets, paper and online test information, and job 
aids all must be changed to reflect test mnemonics 
and specimen type changes.  To prevent specimen 
redraws and delays in patient care, a process to 
manually test specimens should be considered, at 
least initially.  The transition to an EDTA tube may be 
accomplished in anticipation of automation and need 
not be delayed until automation is implemented.
Validation
Vendors provide installation instructions and 
recommendations for verification of instrument op-
erations.  Testing should include a sufficient number 
of positive and negative antibody screens; various 
ABO and D types, including specimens with dual 
populations; and a comparison of results with those 
obtained using the current method.  The validation 
should also include a provision for how discrepant 
results will be resolved.  Obtaining an adequate 
number of different specimens with clinically signifi-
cant antibodies with which to perform sensitivity and 
specificity assessments can be challenging.  Freezing 
samples known to be positive in anticipation of in-
strument validation may be helpful.  However, not all 
antibodies store well.
Vendors do not provide a plan to assess the 
instrument’s operation in terms of meeting the 
facility’s needs.  Actual operating costs, turnaround 
time, instrument repair history, and staff ability to 
operate the instrument should be assessed initially 
and periodically during operations.  Automation 
changes the workflow.  Actual operations will provide 
information about the optimum time between runs, 
the most efficient number of specimens per run, a 
process for changing reagents (because of maximum 
time limits on the instrument), which shift should 
routinely do quality control and maintenance, and a 
process for “rotat(ing) control material testing among 
all operators who perform the test.”11
Clinical Laboratory Improvement Amendments 
(CLIA) regulations require that testing be performed 
according to the manufacturer’s direction.11  This 
includes following the manufacturer’s instructions 
for quality control and periodic maintenance.  When 
two instruments are used, results obtained on the 
same specimens from both instruments should be 
compared.
The Clinical and Laboratory Standards Institute 
(CLSI) has published standards for validation of 
quantitative tests.  While these standards do not 
directly address compatibility testing methods they 
provide insight into planning validation studies.12,13 
Reviewing protocols from other instrument users is 
helpful.
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While combining training and validation to re-
duce the costs for reagents may seem appealing, it 
is best to provide learners with a positive training 
experience.  Problems may occur during validation 
testing that can frustrate the learner.  It may be more 
beneficial to have a few subject matter experts initially 
validate the instrument.  The additional knowledge 
they gain from operating the instrument will better 
prepare them to conduct training.
Service
Instruments do break down.  Probably the most 
common problem is a bent probe because the opera-
tor failed to remove a specimen or reagent closure. 
Some instruments allow the user to change probes 
and replace some parts.  For all other repairs, a ser-
vice call is needed.  Service contracts are available 
for most instruments.  These have variable costs and 
maximum response times.
Training and Competency Assessment
Initial training of staff is most often accomplished 
by sending selected staff members to an offsite train-
ing class.  This creates superusers who are instrument 
experts.  A number of individuals should be trained 
to this level.  It may be useful to separate implemen-
tation into stages.  Once staff are comfortable with 
performing ABO and D typing and antibody screen-
ing, other testing such as DAT, antigen typing, IgG 
crossmatch, and donor ABO/D reconfirmation may 
be added in phases.  Some staff will find automation 
quite challenging and all the various options may be 
overwhelming.
Vendors supply training materials such as videos, 
manuals, and assessment aids but actual practice in 
running the instrument is needed.  This is costly 
in terms of reagents and time.  Performing training 
on a test system interfaced with a computer can be 
challenging.  Creativity is needed to simulate prob-
lems and activate warning messages to provide the 
operator with real-life practice.  Using screenshots 
or pictures in training materials and in written or 
computerized quizzes is invaluable in creating the 
scenarios to assess problem solving skills.  Direct 
observation of staff performance is needed to deter-
mine whether the trainee has acquired appropriate 
psychomotor skills and can perform appropriate 
instrument operations.
Postimplementation Assessment
After implementation it is likely that changes will 
be needed to improve operations or training and 
ameliorate any negative unintended consequences. 
The quantity of reagents needed routinely, frequency 
of testing to maintain staff competency, and other 
logistics will only become evident after operating 
for a few months.  Ongoing assessment of opera-
tions and problems will provide data for revising 
procedures to reduce operator errors, requesting in-
strument enhancements, and evaluating replacement 
instruments.
Conclusion
While still relatively new to the transfusion 
service, automation of transfusion service serology 
has proved itself to be a valuable tool.  The devices 
available are likely to work well in most transfusion 
services.  Although no system is currently available 
that will run on an automation line of a core labora-
tory, there is hope for the future.  The development 
of more sophisticated software that includes auto-
verification protocols is needed to further reduce the 
hands-on time the systems require and increase their 
efficiency.
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